Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLoans and Notes ReceivablesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShort-Term Debt issuances
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Short-Term Debt repayments (2016 - 2023)

Historic Short-Term Debt repayments for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 12 years, with Q2 2023 value amounting to $12.2 million.

  • Lifecore Biomedical, Inc. \De\'s Short-Term Debt repayments rose 2240.0% to $12.2 million in Q2 2023 from the same period last year, while for May 2023 it was $54.6 million, marking a year-over-year increase of 2386.93%. This contributed to the annual value of $146.7 million for FY2024, which is 16849.19% up from last year.
  • Per Lifecore Biomedical, Inc. \De\'s latest filing, its Short-Term Debt repayments stood at $12.2 million for Q2 2023, which was up 2240.0% from $41.6 million recorded in Q1 2023.
  • In the past 5 years, Lifecore Biomedical, Inc. \De\'s Short-Term Debt repayments registered a high of $95.0 million during Q1 2021, and its lowest value of $800000.0 during Q4 2022.
  • Its 5-year average for Short-Term Debt repayments is $22.1 million, with a median of $17.0 million in 2019.
  • In the last 5 years, Lifecore Biomedical, Inc. \De\'s Short-Term Debt repayments soared by 103333.33% in 2019 and then tumbled by 9000.0% in 2022.
  • Quarter analysis of 5 years shows Lifecore Biomedical, Inc. \De\'s Short-Term Debt repayments stood at $37.0 million in 2019, then plummeted by 86.49% to $5.0 million in 2020, then surged by 60.0% to $8.0 million in 2021, then plummeted by 90.0% to $800000.0 in 2022, then skyrocketed by 1430.0% to $12.2 million in 2023.
  • Its Short-Term Debt repayments stands at $12.2 million for Q2 2023, versus $41.6 million for Q1 2023 and $800000.0 for Q4 2022.